 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...453454455456457458459460461462463...522523» |
- | doxorubicin hydrochloride / generics
Journal: The manganese(III) porphyrin MnTnHex-2-PyP modulates intracellular ROS and breast cancer cell migration: Impact on doxorubicin-treated cells. (Pubmed Central) - Mar 23, 2019
Moreover, to explore the cellular mechanisms underlying the observed effects, cell adhesion, spreading, focal adhesions, and NF-κB activation were also studied. Although differential effects were observed according to the endpoints analysed, overall, the alterations induced by MnP in dox-treated cells were consistent with a therapeutically favorable outcome.
- | doxorubicin hydrochloride / generics
Journal: New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties. (Pubmed Central) - Mar 22, 2019
Comparison of structurally close derivatives varying in their position relative to the furan moiety, that is, furan-3-carboxamide 1vs furan-2-carboxamides 5 and 6, revealed fundamental differences in the cytotoxicity profiles, formation of drug-DNA complexes, efficacy of topoisomerase 1 inhibition and mechanisms of tumor cell death. Together with previous SAR data on the role of individual substituents, these results provide evidence that regioisomerization of anthra[2,3-b]furancarboxamides generates the practically perspective derivatives whose properties may vary significantly.
- | doxorubicin hydrochloride / generics
Journal: An ROS-responsive and self-accelerating drug release nanoplatform for overcoming multidrug resistance. (Pubmed Central) - Mar 22, 2019
An 'on-demand' drug release and ROS-responsive nanoparticle was prepared by chemically conjugating hydrophobic α-tocopheryl succinate to hydrophilic poly(ethylene glycol) via a thioketal linker. This nanoparticle encapsulated with doxorubicin and α-tocopheryl succinate exhibited remarkable efficiency in reversing multidrug resistance both in vitro and in vivo.
- | doxorubicin hydrochloride / generics
Preclinical, Journal: In vitro antioxidant and antiproliferative effect of the extracts of Ephedra chilensis K Presl aerial parts. (Pubmed Central) - Mar 22, 2019
The cytotoxic activity and selectivity of the non-polar extracts of E. chilensis for the MCF-7 and PC-3 cell lines could be related to the terpenic compounds and fatty acids of the extracts or to the synergistic effect of all of the compounds in the extracts. These non-polar extracts can be used for the development of new drugs against breast and prostate cancer.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Review, Journal: Management of adults with Burkitt lymphoma. (Pubmed Central) - Mar 22, 2019
The infusional regimen of dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and regular- or double-dose rituximab (DA-EPOCH-R or -RR) is less toxic than standard BL regimens, yet maintains high rates of cure across a diverse range of patients, including those with disseminated disease, advanced age, and HIV infection...Still, patients with CNS involvement remain at high risk for early death, and prevention of late CNS relapses remains a priority. Future studies combining rational targeted agents with DA-EPOCH-R or -RR may further improve the cure rate.
- | doxorubicin hydrochloride / generics
Clinical, Journal: Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type. (Pubmed Central) - Mar 22, 2019
The results further relate previous NP transport studies to efficacy, as a function of surface-modification and cell type. Longer-term, this information may help guide the design of NP-mediated strategies to maximize efficacy based on patient-specific cervical tumor origin and characteristics.
- | doxorubicin hydrochloride / generics
Journal: Cholic Acid-Conjugated Methylcellulose-Polyethylenimine Nano-Aggregates for Drug Delivery Systems. (Pubmed Central) - Mar 22, 2019
...MCPEI-CA could encapsulate the anticancer drug doxorubicin (Dox) with 58.0% of drug loading content and 23.2% of drug loading efficiency and its release was facilitated in acidic condition...MCPEI-CA/Dox nano-aggregates showed concentration-dependent anticancer activity, which could overcome the multidrug resistance of cancer cells. In this work, molecular conformation change of MC derivatives by chemical modification and a potential of MCPEI-CA/Dox nano-aggregates for drug delivery systems were revealed.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Automated Segmentation of Light-Sheet Fluorescent Imaging to Characterize Experimental Doxorubicin-Induced Cardiac Injury and Repair. (Pubmed Central) - Mar 21, 2019
Treatment with the γ-secretase inhibitor, DAPT, to inhibit cleavage and release of Notch Intracellular Domain (NICD) blocked cardiac architectural regeneration and restoration of ventricular function at day 60 (P < 0.05, n = 6-14). Our approach provides a high-throughput model with translational implications for drug discovery and genetic modifiers of chemotherapy-induced cardiomyopathy.
- | paclitaxel / Generic mfg., doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. (Pubmed Central) - Mar 21, 2019
However, RS did not significantly predict benefit from adding paclitaxel to AC chemotherapy. (Trial Registration: PDQ: NSABP-B-28).
- | doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Excellent Outcomes Following Response-based Omission of Radiotherapy in Children and Adolescents With Intermediate or High-risk Hodgkin Lymphoma. (Pubmed Central) - Mar 21, 2019
Their outcome was compared with a historical cohort (n=42) treated with Stanford V or ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine), who received consolidative involved-field RT...When administered, RT was restricted to only sites of inadequate early response. Results of large prospective studies are needed to validate these findings.
- | doxorubicin hydrochloride / Generic mfg.
Clinical, Review, Journal: Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review. (Pubmed Central) - Mar 21, 2019
On the basis of our model, current dosing regimens-doxorubicin doses >375 mg/m without dexrazoxane-overvalue increased anthracycline administration and may contribute to devastating cardiotoxicity. The linear increase of cardiotoxicity without evidence of plateau confirms the necessity for lifelong cardiac monitoring.
- | doxorubicin hydrochloride / Generic mfg.
Journal: Mitochondrial accumulation of doxorubicin in cardiac and diaphragm muscle following exercise preconditioning. (Pubmed Central) - Mar 21, 2019
We hypothesized that exercise may induce protection by increasing the expression of mitochondria-specific ATP-binding cassette (ABC) transporters and reducing mitochondrial DOX accumulation. Our results confirm this finding and demonstrate that two weeks of exercise preconditioning is sufficient to prevent cardiorespiratory dysfunction.
- || Rituxan (rituximab) / Roche, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed: NCI-2015-00960: Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 21, 2019
P2, N=131, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Our results confirm this finding and demonstrate that two weeks of exercise preconditioning is sufficient to prevent cardiorespiratory dysfunction. Recruiting --> Active, not recruiting
- | Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Phase classification, Metastases: GAZELLE: An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma (clinicaltrials.gov) - Mar 21, 2019
P4, N=112, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Phase classification: P2 --> P4
- | L1-10 / Amgen, Opdivo (nivolumab) / BMS
Enrollment open, PD(L)-1 Biomarker, Metastases: Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% (clinicaltrials.gov) - Mar 21, 2019
P2, N=22, Recruiting, Sponsor: National Cancer Center, Korea
Phase classification: P2 --> P4 Not yet recruiting --> Recruiting
- ||| Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku
Enrollment open, Metastases: GAZELLE: An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma (clinicaltrials.gov) - Mar 20, 2019
P2, N=112, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme, Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
New P1/2 trial, Surgery: TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery (clinicaltrials.gov) - Mar 20, 2019
P1/2, N=67, Not yet recruiting, Sponsor: Samsung Medical Center
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Lartruvo (olaratumab) / Eli Lilly
Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma (clinicaltrials.gov) - Mar 18, 2019
P1, N=0, Withdrawn, Sponsor: University of Miami
Not yet recruiting --> Recruiting N=30 --> 0 | Trial completion date: Oct 2022 --> Jun 2023 | Initiation date: Feb 2019 --> Jun 2019 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2020 --> Jun 2021
- | cisplatin / Generic mfg.
Trial completion date, Trial primary completion date, Surgery: Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery (clinicaltrials.gov) - Mar 18, 2019
P2/3, N=1220, Recruiting, Sponsor: Children's Oncology Group
N=30 --> 0 | Trial completion date: Oct 2022 --> Jun 2023 | Initiation date: Feb 2019 --> Jun 2019 | Recruiting --> Withdrawn | Trial primary completion date: Oct 2020 --> Jun 2021 Trial completion date: Mar 2025 --> Jun 2025 | Trial primary completion date: Mar 2025 --> Jun 2025
- | New P1 trial, PD(L)-1 Biomarker: Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov) - Mar 18, 2019
P1, N=52, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. (Pubmed Central) - Mar 16, 2019
We aimed at evaluating the NLR as predictive for complete response (CR) and prognostic for progression-free (PFS) and overall survival (OS) in a study cohort of 121 Peruvian patients with diffuse large B-cell lymphoma (DLCBL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP)...NLR ≥6 was prognostic of PFS and OS after adjusting for the International Prognostic Index and the NCCN-IPI scores. In conclusion, the NLR could add predictive and prognostic value to well established prognostic tools in DLBCL.
- | Trial completion, Metastases: High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma (clinicaltrials.gov) - Mar 15, 2019
P3, N=109, Completed, Sponsor: Children's Oncology Group
In conclusion, the NLR could add predictive and prognostic value to well established prognostic tools in DLBCL. Active, not recruiting --> Completed
- ||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment open, Combination therapy: ISAKIDS: Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (clinicaltrials.gov) - Mar 15, 2019
P2, N=96, Recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | mivavotinib (CB-659) / Calithera, Rituxan (rituximab) / Roche
Enrollment open, Trial completion date, Trial primary completion date: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - Mar 15, 2019
P1, N=18, Recruiting, Sponsor: Northwestern University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2020 --> Aug 2021
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, FDG PET: BRAPP2: Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD (clinicaltrials.gov) - Mar 14, 2019
P2, N=40, Active, not recruiting, Sponsor: The Lymphoma Academic Research Organisation
Not yet recruiting --> Recruiting | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2020 --> Aug 2021 Recruiting --> Active, not recruiting
- | Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Combination therapy, Surgery, Metastases: Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 14, 2019
P1b, N=36, Recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: Dec 2020 --> Jun 2022 | Trial primary completion date: Dec 2018 --> Jun 2020
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed, PD(L)-1 Biomarker: NU 16H08: PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma (clinicaltrials.gov) - Mar 14, 2019
P2, N=30, Active, not recruiting, Sponsor: Northwestern University
Trial completion date: Dec 2020 --> Jun 2022 | Trial primary completion date: Dec 2018 --> Jun 2020 Recruiting --> Active, not recruiting
- |||| oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P2 trial: Neo-CheckRay: Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (clinicaltrials.gov) - Mar 13, 2019
P2, N=147, Not yet recruiting, Sponsor: Jules Bordet Institute
- | New P2 trial: Treatment of Malignant Peritoneal Mesothelioma (MESOTIP) (clinicaltrials.gov) - Mar 13, 2019
P2, N=66, Not yet recruiting, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
- || triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
Trial completion date, Trial primary completion date, Metastases: PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (clinicaltrials.gov) - Mar 13, 2019
P1/2, N=56, Recruiting, Sponsor: Prescient Therapeutics, Ltd.
Recruiting --> Active, not recruiting Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, Trial primary completion date: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma (clinicaltrials.gov) - Mar 13, 2019
P1/2, N=70, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Oct 2021
- | Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Trial completion date, Combination therapy: Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+ (clinicaltrials.gov) - Mar 13, 2019
P3, N=250, Active, not recruiting, Sponsor: The Lymphoma Academic Research Organisation
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Oct 2021 Trial completion date: Feb 2019 --> Jan 2021
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date: EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov) - Mar 13, 2019
P2, N=366, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial completion date: Feb 2019 --> Jan 2021 Trial completion date: Jan 2031 --> May 2031 | Initiation date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2024 --> May 2024
- | Keytruda (pembrolizumab) / Merck (MSD), Asparlas (calaspargase pegol-mknl) / Servier, Takeda, Leadiant Biosci, Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open, Trial initiation date, Metastases: Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma (clinicaltrials.gov) - Mar 13, 2019
P1, N=40, Recruiting, Sponsor: New York Medical College
Trial completion date: Jan 2031 --> May 2031 | Initiation date: Jan 2019 --> May 2019 | Trial primary completion date: Jan 2024 --> May 2024 Not yet recruiting --> Recruiting | Initiation date: Nov 2018 --> Mar 2019
- | doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial termination: 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer (clinicaltrials.gov) - Mar 12, 2019
P2, N=15, Terminated, Sponsor: Advanced Accelerator Applications
Not yet recruiting --> Recruiting | Initiation date: Nov 2018 --> Mar 2019 N=30 --> 15 | Recruiting --> Terminated; Sponsor Decision based on strategic considerations
- | veliparib (ABT-888) / AbbVie
Clinical, P3 data, Journal, BRCA Biomarker, PARP Biomarker: Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. (Pubmed Central) - Mar 8, 2019
P3
Increased toxicities with the addition of carboplatin (with or without veliparib) to paclitaxel were manageable and did not substantially affect treatment delivery of paclitaxel followed by doxorubicin and cyclophosphamide. Given the consistent results with previous studies, the addition of carboplatin appears to have a favourable risk to benefit profile and might be considered as a potential component of neoadjuvant chemotherapy for patients with high-risk, triple-negative breast cancer.
- | Decadron (dexamethasone) / Merck (MSD), doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031. (Pubmed Central) - Mar 8, 2019
Thus, in a well-defined and standardized protocol, the RPD distributions for AYA patients will be similar to those for pediatric population. However, the increased cumulative incidence of relapse in the AYA patients who had received IFRT compared with the pediatric population requires further exploration, given the potential differences in clinical outcomes in the AYA population.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. (Pubmed Central) - Mar 8, 2019
Dose-adjusted rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) has produced good outcomes in primary mediastinal B-cell lymphoma (PMBCL), but predictors of resistance to this treatment are unclear...Univariate analysis of posttreatment variables revealed that residual CT tumor volume, maximum standardized uptake value, and Deauville score were associated with PFS; a Deauville score of 5 remained significant on multivariable analysis (P = .006). A model combining baseline TLG and end-of-therapy Deauville score identified patients at increased risk of progression.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, Journal: Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. (Pubmed Central) - Mar 8, 2019
Pertuzumab-based regimens, including THP, resulted in higher pCR rates as compared to ddAC-TH, with the THP regimen associated with the best tolerability among patients with localized HER2+ breast cancer. Given the various neoadjuvant regimens, additional studies are needed to determine optimal treatment sequencing and escalation/de-escalation strategies to personalize neoadjuvant regimens for localized HER2+ breast cancer.
- | Trial completion date, Trial primary completion date: Vaccination of High Risk Breast Cancer Patients (clinicaltrials.gov) - Mar 8, 2019
P1/2, N=61, Enrolling by invitation, Sponsor: University of Arkansas
Given the various neoadjuvant regimens, additional studies are needed to determine optimal treatment sequencing and escalation/de-escalation strategies to personalize neoadjuvant regimens for localized HER2+ breast cancer. Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020
- ||||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Trial completion, Trial completion date: A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (clinicaltrials.gov) - Mar 7, 2019
P3, N=174, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2019 --> Feb 2020 Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018
- | thioguanine / Generic mfg., dasatinib / Generic mfg.
Trial suspension: AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov) - Mar 7, 2019
P3, N=5956, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Nov 2018 Recruiting --> Suspended
- | doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial suspension, Trial primary completion date: Myocardial Perfusion and Fibrosis in Cancer Survivors (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=16, Suspended, Sponsor: Wake Forest University Health Sciences
Recruiting --> Suspended Trial completion date: Dec 2018 --> Dec 2019 | Recruiting --> Suspended | Trial primary completion date: Dec 2018 --> Dec 2019
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. (Pubmed Central) - Mar 7, 2019
Trial completion date: Dec 2018 --> Dec 2019 | Recruiting --> Suspended | Trial primary completion date: Dec 2018 --> Dec 2019 R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. (Pubmed Central) - Mar 7, 2019
R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease. By using a less intense induction, this regimen can serve as a platform for combined use of novel agents, with less risk of additive toxicity.
- | Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical, Journal: Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). (Pubmed Central) - Mar 6, 2019
By using a less intense induction, this regimen can serve as a platform for combined use of novel agents, with less risk of additive toxicity. VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL.
- || Lartruvo (olaratumab) / Eli Lilly
Enrollment change, Metastases: A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 6, 2019
P1b, N=24, Active, not recruiting, Sponsor: Eli Lilly and Company
VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL. N=60 --> 24
- ||||| plinabulin (BPI 2358) / BeyondSpring
Enrollment closed: PROTECTIVE-2: Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia (clinicaltrials.gov) - Mar 6, 2019
P2/3, N=237, Active, not recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
N=60 --> 24 Recruiting --> Active, not recruiting
- | Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
New P1 trial, Combination therapy, Monotherapy: Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda (clinicaltrials.gov) - Mar 6, 2019
P1, N=40, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | cisplatin / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed, BRCA Biomarker: Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa (clinicaltrials.gov) - Mar 5, 2019
P2, N=170, Active, not recruiting, Sponsor: Beth Israel Deaconess Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting